CCC
CL icon

Crescent Capital Consulting’s Colgate-Palmolive CL Stock Holding History

Crescent Capital Consulting’s Portfolio CL Stock Details CL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$474K Buy
5,534
+10
+0.2% +$781 0.08% 123
2021
Q3 		$418K Hold
5,524
– – 0.08% 126
2021
Q2 		$450K Hold
5,524
– – 0.08% 112
2021
Q1 		$436K Buy
5,524
+1,184
+27% +$92.8K 0.1% 112
2020
Q4 		$371K Buy
+4,340
New +$359K 0.1% 111

Other funds holding CL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Crescent Capital Consulting's CL Position: Q4 2021 in Review

Crescent Capital Consulting increased its Colgate-Palmolive (CL) stake by 0.18% in Q4 2021, buying an estimated $781 and bringing the position to 5,534 shares worth $474K. The position accounts for 0.08% of the portfolio, ranked #123.

Crescent Capital Consulting first reported a position in CL in Q4 2020 and has held it in 5 quarters since. 1,704 funds tracked by Wall St. Rank hold CL as of Q4 2021.

  • Crescent Capital Consulting held 5,534 shares of Colgate-Palmolive worth $474K as of Q4 2021.
  • Crescent Capital Consulting bought 10 Colgate-Palmolive shares in Q4 2021, an estimated $781.
  • Colgate-Palmolive made up 0.08% of Crescent Capital Consulting's portfolio in Q4 2021, its #123 holding.
  • Crescent Capital Consulting first reported a position in Colgate-Palmolive in Q4 2020 and has held it in 5 quarters since.
  • 1,704 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.